Field of Use

A field of use restriction is a clause in a patent license agreement that limits the licensee's right to practice the licensed patent to a specified commercial, technical, or product application: DEFINITION: a field of use defines the boundary of what the licensee is permitted to do with the licensed patent; the licensor retains the right to practice the patent in all other fields and to license those fields to others; COMMON EXAMPLES: PHARMACEUTICAL: license for human therapeutic use only (excluding veterinary); license for cancer indications only (excluding cardiovascular); license for oral formulations only (excluding injectables); TECHNOLOGY: license for consumer electronics only (excluding aerospace or defense); license for mobile applications only (excluding enterprise software); license for voice processing only (excluding text analytics); MATERIALS: license for use in automotive applications only (excluding construction); INDUSTRIAL: license for use in food processing only (excluding chemical manufacturing); PURPOSE OF FIELD OF USE RESTRICTIONS: REVENUE SEGMENTATION: allows the licensor to charge separately for each market segment; a single patent may generate 3-5x the revenue of a single license by segmenting fields; COMPETITIVE SEPARATION: allows the licensor to maintain exclusivity in one field while licensing competitors in others; RISK ALLOCATION: enables licensing in fields where the licensor does not itself operate (no business conflict); REGULATORY COMPLIANCE: in pharmaceutical licensing, different fields often correspond to different regulatory approval paths; STRATEGIC CONTROL: licensor retains leverage over fields it may want to enter or license to preferred partners in the future.

Field of use definitions are one of the most disputed provisions in patent licenses — imprecise definitions lead to disputes: COMMON DEFINITIONAL FRAMEWORKS: (a) BY INDUSTRY/APPLICATION: 'use in the field of oncology therapeutics'; 'use in automotive original equipment manufacturing'; 'use in consumer packaged goods manufacturing'; advantages: broad coverage; disadvantages: industry boundaries shift; (b) BY PRODUCT TYPE: 'use in semiconductor wafer fabrication'; 'use in wearable electronic devices'; 'use in packaged injectable pharmaceutical products'; advantages: more specific; disadvantages: technology converges and blurs product categories; (c) BY CUSTOMER SEGMENT: 'use in direct-to-consumer sales channels'; 'use for pharmaceutical companies with annual revenues under $1 billion'; advantages: can tier pricing by ability to pay; disadvantages: customer segment classification disputes; (d) BY REGULATORY CATEGORY: 'use in FDA-regulated devices under 21 CFR Part 800 series'; 'use in clinical laboratory applications under CLIA'; advantages: clear regulatory classification; disadvantages: regulatory categories change; (e) BY TECHNICAL PARAMETER: 'use in frequencies above 6 GHz'; 'use in applications requiring operating temperatures above 200 degrees Celsius'; advantages: technically precise; disadvantages: may be circumvented by slight technical variation; COMMON DRAFTING MISTAKES: vague industry description (internet of things could mean many things); outdated regulatory references; overlapping definitions creating ambiguity about which license covers a particular product; KEY PROVISION: 'no other fields' clause — licensor represents it has not granted another license for this specific field; prevents the scenario where the licensee's field is already licensed to a competitor.

Field of use restrictions have generated significant patent and antitrust litigation: PATENT MISUSE DOCTRINE: using a patent to extend its scope through licensing restrictions can constitute patent misuse; field of use restrictions that effectively restrain commerce beyond the patent's scope may be challenged; modern courts are deferential to field of use restrictions: General Talk & Film v. Eastman Kodak: narrow use restrictions within the scope of the patent are valid; restrictions that extend to unpatented products or beyond the patent term may be misuse; ANTITRUST ANALYSIS: field of use restrictions between competitors may implicate antitrust law; horizontal agreements (same technology, competing products) are more suspect than vertical (licensor to downstream licensee); per se illegality for market division between competitors (rare); rule of reason analysis for most field of use restrictions; SPILLOVER USE: what happens if the licensee's product crosses into an unlicensed field?; this is infringement (the licensee has exceeded its licensed rights); common in technology that straddles multiple application areas; ROYALTY IMPLICATIONS OF FIELD OF USE: a narrower field of use = lower royalty (less market access); an exclusive field of use = higher royalty (competitive advantage for that field); FIELD OF USE AND IMPROVEMENTS: does the field of use restriction apply to improvements to the licensed technology?; typically yes, unless the license expressly includes an improvement grant in all fields; GRANT-BACK CLAUSES: if the license includes a grant-back of improvements, the field of use of the grant-back may differ from the main license; narrow grant-back (only in the licensed field) vs. broad grant-back (all fields); LEGAL TEST FOR FIELD OF USE SCOPE: the field of use restriction is interpreted under general contract principles; ambiguities are construed against the drafter in some jurisdictions; extrinsic evidence of the parties' intent may be considered.

Field of use restrictions are a central element of royalty rate optimization and multi-market licensing strategy: TIERED ROYALTY STRATEGY: a single patent may cover technology with different economic value in different markets; field of use licensing allows the licensor to price each market separately: high-value field (pharma/biotech): 5-15% of net sales; commodity field (consumer electronics): 1-3% of net sales; industrial/OEM field: 2-5% of net sales; total revenue from all fields may be 3-5x a single non-field-limited license; EXCLUSIVITY PREMIUM BY FIELD: exclusive license within a field commands a higher royalty than non-exclusive in the same field; exclusivity premium: 25-100% above non-exclusive rate depending on market dynamics; FIELD OF USE AND PATENT STRENGTH: narrow field of use: each licensee pays a lower rate but licensee count is higher; broad field of use: higher rate per licensee but fewer licensees needed; MILESTONE PAYMENTS BY FIELD: in pharmaceutical licensing, milestones are typically tied to regulatory events in specific fields: Phase I initiation in field X: $1M; Phase III initiation: $5M; FDA approval: $25M; first commercial sale: 7% running royalty; CROSS-LICENSING AND FIELD INTERACTION: companies with complementary technology may cross-license in different fields; each company licenses the other in the field where it is commercially active; PRACTICAL EXAMPLE: a technology patent covering a new polymer: field A: automotive structural components (exclusive) — $5M upfront + 3% royalties; field B: consumer packaging (non-exclusive) — $1M upfront + 2% royalties to 5 licensees; field C: medical implants (exclusive) — $10M upfront + 6% royalties; total deal value exceeds what a single field license would generate.

Exceeding a field of use restriction is a breach of license and potentially patent infringement: LEGAL CONSEQUENCES: BREACH OF LICENSE: using the licensed patent outside the licensed field is a breach of the license agreement; gives the licensor the right to: terminate the license; sue for breach of contract damages; seek injunctive relief; PATENT INFRINGEMENT: exceeding the license scope also constitutes patent infringement (no license covers the out-of-field use); the patent owner may sue for: injunctive relief; infringement damages (reasonable royalty or lost profits); willful infringement damages if the licensee knew the use was out-of-scope; DETECTION: field of use violations are detected through: product audits (the licensee sells products in markets outside the licensed field); customer lists (products appearing with unlicensed customer categories); marketplace monitoring; royalty audit (auditor identifies products classified outside the royalty base that actually practice the patent); TYPICAL DISPUTES: technology converges and what started as a licensed application expands into unlicensed markets; a pharmaceutical company with a license for 'oncology' develops a product used off-label in other indications; a semiconductor company licensed for 'consumer products' begins selling to automotive OEMs; RESOLUTION OPTIONS: retroactive license expansion: negotiate to add additional fields in exchange for additional consideration; the out-of-field use is deemed licensed retroactively; amendment to the license agreement; AUDIT PROVISION IMPORTANCE: audit clauses that include field of use monitoring (not just royalty rate accuracy) help detect out-of-field use; licensees should proactively seek license amendments before expanding into adjacent markets.